PuraPharm Corporation Limited (HKG:1498)
Hong Kong · Delayed Price · Currency is HKD 0.2800
0.00 (0.00%)
Aug 27, 2026, 4:08 PM HKT
PuraPharm Corporation Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 323.49 | 336.11 | 382.09 | 406.86 | 448.07 | 659.59 | |
Revenue Growth | -6.71% | -12.03% | -6.09% | -9.20% | -32.07% | 9.60% |
Cost of Revenue | 146.14 | 155.96 | 176.95 | 190.23 | 185.37 | 236.24 |
Gross Profit | 177.35 | 180.16 | 205.14 | 216.63 | 262.7 | 423.35 |
Selling, General & Admin | 194.37 | 204.54 | 224.39 | 263.18 | 315.3 | 388.46 |
Other Operating Expenses | 3.18 | - | - | 3.93 | 5.11 | 2.73 |
Operating Expenses | 188.64 | 196.38 | 223.39 | 269.83 | 330.95 | 408.22 |
Operating Income | -11.3 | -16.22 | -18.25 | -53.2 | -68.25 | 15.14 |
Interest Expense | -22.09 | -20.72 | -23.71 | -27.41 | -24.18 | -27.03 |
Interest & Investment Income | 0.04 | 0.04 | 0.35 | 0.29 | 0.48 | 0.36 |
Earnings From Equity Investments | -0.22 | -0.09 | -0.31 | -0.15 | - | - |
Currency Exchange Gain (Loss) | - | - | - | -0.41 | -0.08 | 0.71 |
Other Non Operating Income (Expenses) | 9.71 | 6.53 | 4.44 | 9.24 | 12.25 | 1.22 |
EBT Excluding Unusual Items | -23.86 | -30.46 | -37.49 | -71.63 | -79.79 | -9.6 |
Impairment of Goodwill | - | - | - | -3.05 | - | -67.35 |
Gain (Loss) on Sale of Investments | -0.57 | -0.57 | - | -0 | 0.17 | 0.3 |
Gain (Loss) on Sale of Assets | -2.09 | -2.09 | 11.12 | 2.02 | 1.73 | -0.01 |
Asset Writedown | -1.29 | -1.29 | -2.77 | -29.66 | -41.3 | -48.66 |
Other Unusual Items | - | - | - | - | - | 8.12 |
Pretax Income | -27.81 | -34.41 | -29.14 | -102.31 | -119.18 | -117.19 |
Income Tax Expense | -0.15 | 0.81 | 6.3 | 3.77 | 1.03 | 4.69 |
Net Income | -27.66 | -35.22 | -35.44 | -106.08 | -120.21 | -121.88 |
Preferred Dividends & Other Adjustments | -0 | -0 | - | - | - | - |
Net Income to Common | -27.66 | -35.22 | -35.44 | -106.08 | -120.21 | -121.88 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 489 | 419 | 395 | 395 | 395 | 394 |
Shares Outstanding (Diluted) | 489 | 419 | 395 | 395 | 395 | 394 |
Shares Change | 23.78% | 6.00% | - | 0.12% | 0.22% | 6.01% |
EPS (Basic) | -0.06 | -0.08 | -0.09 | -0.27 | -0.30 | -0.31 |
EPS (Diluted) | -0.06 | -0.08 | -0.09 | -0.27 | -0.30 | -0.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.48 | 28.24 | 89.18 | 60.43 | 67.68 | -17.61 |
Free Cash Flow Per Share | -0.01 | 0.07 | 0.23 | 0.15 | 0.17 | -0.04 |
Gross Margin | 54.82% | 53.60% | 53.69% | 53.24% | 58.63% | 64.18% |
Operating Margin | -3.49% | -4.83% | -4.78% | -13.08% | -15.23% | 2.30% |
Profit Margin | -8.55% | -10.48% | -9.28% | -26.07% | -26.83% | -18.48% |
Free Cash Flow Margin | -2.00% | 8.40% | 23.34% | 14.85% | 15.10% | -2.67% |
EBITDA | 8.82 | 6.23 | 15.25 | -29.15 | -42.11 | 40.12 |
EBITDA Margin | 2.73% | 1.85% | 3.99% | -7.17% | -9.40% | 6.08% |
D&A For EBITDA | 20.11 | 22.45 | 33.49 | 24.05 | 26.14 | 24.98 |
EBIT | -11.3 | -16.22 | -18.25 | -53.2 | -68.25 | 15.14 |
EBIT Margin | -3.49% | -4.83% | -4.78% | -13.08% | -15.23% | 2.30% |